These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36967671)

  • 1. Cross-reactivity between piperacillin-tazobactam and cefoperazone-sulbactam in drug-induced immune thrombocytopenia.
    He X; Huang W; Wan X; Li X; Chang Q; Ding L
    J Int Med Res; 2023 Mar; 51(3):3000605231162434. PubMed ID: 36967671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients.
    Chen Y; Xiang Q; Liu L
    J Int Med Res; 2021 May; 49(5):3000605211019661. PubMed ID: 34057835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia.
    Lai CC; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Tu CY; Cheng WC; Chen CH
    Medicine (Baltimore); 2023 Jul; 102(28):e34284. PubMed ID: 37443505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
    Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
    J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of cefoperazone sulbactam and piperacillin tazobactam on mortality in Gram-negative nosocomial infections.
    Guclu E; Kaya G; Ogutlu A; Karabay O
    J Chemother; 2020 May; 32(3):118-123. PubMed ID: 32096456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid-Onset Thrombocytopenia Following Piperacillin-Tazobactam Reexposure.
    Nguyen VD; Tourigny JF; Roy R; Brouillette D
    Pharmacotherapy; 2015 Dec; 35(12):e326-30. PubMed ID: 26684560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
    Wang H; Chen MJ;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
    McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
    Huang CT; Chen CH; Chen WC; Wang YT; Lai CC; Fu PK; Kuo LK; Chen CM; Fang WF; Tu CY; Ku SC
    Int J Antimicrob Agents; 2022 Jan; 59(1):106491. PubMed ID: 34871744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia.
    Beaulieu C; Kurczewski L; Yajnik V
    J Thromb Thrombolysis; 2019 Jul; 48(1):167-170. PubMed ID: 30968302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature.
    Alzahrani M; Alrumaih I; Alhamad F; Abdel Warith A
    Platelets; 2018 Sep; 29(6):628-631. PubMed ID: 29863943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/tazobactam-induced immune-mediated thrombocytopenia in the intensive care unit.
    Boyce K; Brar H; Stabler SN
    J Clin Pharm Ther; 2016 Dec; 41(6):730-732. PubMed ID: 27670947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
    Frank U; Mutter J; Schmidt-Eisenlohr E; Daschner FD
    Clin Microbiol Infect; 2003 Nov; 9(11):1128-32. PubMed ID: 14616732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
    Aynioglu A; Mutlu B; Hacihanefioglu A
    Rev Esp Quimioter; 2016 Apr; 29(2):69-75. PubMed ID: 26888338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid-onset piperacillin-tazobactam induced thrombocytopenia.
    Shaik S; Kazi HA; Ender PT
    J Pharm Pract; 2015 Apr; 28(2):204-6. PubMed ID: 25609660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
    Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
    New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.